S-1: TriSalus Life Sciences Files for Resale of Shares Issuable Upon Warrant Exercise

TriSalus Life Sciences is registering for resale up to 130,805 shares of its common stock issuable upon the exercise of a warrant held by OrbiMed.

Summary

• TriSalus Life Sciences has filed a registration statement for the resale of up to 130,805 shares of its common stock.
• These shares are issuable upon the exercise of a warrant held by OrbiMed Royalty & Credit Opportunities IV, LP.
• The warrant was granted to OrbiMed in connection with a credit agreement dated April 30, 2024.
• TriSalus will not receive any proceeds from the sale of these shares by OrbiMed.
• The company will bear the costs associated with the registration, while OrbiMed will cover any commissions or discounts from its sales.
• As of June 11, 2024, TriSalus had 27,159,333 shares of common stock outstanding.
• After giving effect to the issuance of the shares registered for resale, the total outstanding shares would be 27,290,138.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It describes the terms of a share resale, which is neither inherently positive nor negative.

Positives

• The registration statement fulfills certain registration rights granted to OrbiMed.
• TriSalus will bear all costs, expenses and fees in connection with the registration of the Common Stock.

Negatives

• TriSalus will not receive any proceeds from the sale of shares of its Common Stock by the Selling Securityholder.

Risks

• Investing in the company's securities involves a high degree of risk, as detailed in the Risk Factors section of the prospectus.
• The company has a limited operating history and has incurred significant losses since its inception.
• The company may require substantial additional capital to finance its operations and continue development of its product candidates.
• The company's revenue is primarily generated from sales of its TriNav device, making it highly dependent on its success.
• The company is early in its pharmaceutical development efforts with only one pharmaceutical product candidate, nelitolimod, in early clinical development.

Future Outlook

The Selling Securityholder may offer and sell the securities covered by this prospectus in a number of different ways and at varying prices.

Industry Context

This announcement is typical for companies that have recently completed a merger or financing and are fulfilling obligations to register shares for resale by investors.

Stakeholder Impact

• The resale of shares may have an impact on the market price of the company's stock.

Next Steps

• The Selling Securityholder may offer and sell the securities covered by this prospectus in a number of different ways and at varying prices.

Key Dates

Keywords

resale, common stock, OrbiMed, warrant, registration statement, TriSalus Life Sciences, TLSI, shares